MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) will report second-quarter 2026 financial results before the market opens Aug. 6 and hold a conference call later that morning to discuss its performance and clinical development programs.
The biotechnology company scheduled the call for 8:30 a.m. Eastern Time on Thursday, Aug. 6.
U.S. participants may join by calling (800) 715-9871. International participants may call (646) 307-1963. The conference identification number is 2222566.
A live webcast will be available through the events section of Ocugen’s investor relations website at https://ir.ocugen.com/.
The company plans to make a replay and archived webcast available on the same site following the call.
Ocugen is developing modifier gene therapies for inherited retinal diseases and other causes of blindness. Its programs target conditions including retinitis pigmentosa, Stargardt disease and geographic atrophy, an advanced form of dry age-related macular degeneration.
The company’s platform is designed to address disease biology across multiple gene networks rather than target a single genetic mutation.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.